Meu SciELO
Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Citado por Google
- Similares em SciELO
- Similares em Google
Compartilhar
Farmacia Hospitalaria
versão On-line ISSN 2171-8695versão impressa ISSN 1130-6343
Resumo
FERNANDEZ-RIBEIRO, Francisca; OLIVERA-FERNANDEZ, Rosario e CRESPO-DIZ, Carlos. Adherence and safety study in patients on treatment with capecitabine. Farm Hosp. [online]. 2017, vol.41, n.2, pp.204-221. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.2017.41.2.10596.
Background:
The introduction of oral antineoplastic agents in therapeutics has caused a change in the treatment strategy against cancer. The objective of this study was to analyze the adherence in patients to treatment with capecitabine, their adverse events, and the overall health status of patients, as well as the relationship of these factors with adherence.
Method:
An observational, prospective study at 7 months, in a cohort of patients on capecitabine treatment, including treatment initiations and continuations, regardless of diagnosis or indication. The data collected were: demographic variables (age, gender), diagnostic (breast cancer, colorectal cancer, gastric cancer, off-label), adherence (tablet count, Morisky test, Sackett test), safety (assessment of adverse events, clinical evaluation by the oncologist) and quality of life (performance status, SF-12 test).
Data sources:
electronic clinical records (IANUS®), dispensing program for outpatients (SILICON®) and interviews with patients.
Results:
There were 111 evaluable patients, with a mean age of 66.7 years (range 32-86), ECOG PS 1 in 76.6%. Adherence level: 78.4% (81.7% in the initiation subgroup vs. 72.5% in the continuation subgroup). Adverse events: skin toxicity (33.33%), asthenia (25.22%), gastrointestinal toxicity (24.32%) and neurological toxicity (24.32%), mostly G1. Health status, SF-12 test: subjective evaluation as “good” in 33.30% of cases.
Conclusions:
The low level of adherence in the continuation subgroup can be associated with the duration of treatment, toxicities, clinical evolution, and perception of their health status. It is necessary to conduct individualized monitoring in this group of patients in order to obtain a favorable clinical response.
Palavras-chave : Adherence; Capecitabine; Adverse Events; Quality of life; Pharmaceutical care.